Trial Condition(s):

Atrial Fibrillation

Analysis of the Potential savings of Rivaroxaban Events versus Vitamin K Antagonists events

Bayer Identifier:

18231

ClinicalTrials.gov Identifier:

NCT03462446

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.

Inclusion Criteria
- Older than 18 years
- Diagnosis of non-valvular AF (ICD code 427.31) 
- Pharmacological treatment with VKAs or rivaroxaban  following diagnosis
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
249
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
N/A

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Granada, Spain

Status
Completed
 

Trial Design